Form 4: SpringWorks Therapeutics Director Julie Hambleton Executes Stock Option and Sells Shares
SEC Form 4 Filing
Director Julie Hambleton exercised stock options and sold shares of SpringWorks Therapeutics (SWTX) on February 10, 2025, according to a Form 4 filing with the SEC.
Summary
- On February 10, 2025, Julie Hambleton, a director of SpringWorks Therapeutics, Inc. (SWTX), exercised stock options to acquire 13,774 shares of common stock at a price of $32.27 per share.
- Simultaneously, Hambleton sold 13,774 shares of common stock at a weighted average price of $53.0134, with prices ranging from $39.02 to $40.01.
- Following these transactions, Hambleton directly owns 4,095 shares of SpringWorks Therapeutics.
- The transactions were executed according to a pre-arranged trading plan under Rule 10b5-1, adopted on March 1, 2024.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it simply reports transactions by a company director. The use of a 10b5-1 plan suggests a pre-planned strategy, reducing the impact of the transaction on market sentiment.
Industry Context
Form 4 filings are standard disclosures required by the SEC when company insiders, like directors and officers, trade their company's stock. These filings are closely watched by investors for insights into management's perspective on the company's value and future prospects.
Comparison to Industry Standards
- It's common for directors to have stock options as part of their compensation.
- The use of a 10b5-1 trading plan is a standard practice to avoid accusations of insider trading, as it allows insiders to sell shares at predetermined times and prices.
- Comparable companies in the biotechnology sector, such as BioMarin Pharmaceutical and Vertex Pharmaceuticals, also see regular Form 4 filings from their directors and officers.
Stakeholder Impact
- The transactions may have a minor impact on shareholders as they provide insight into the director's financial activities related to the company's stock.
- The use of a 10b5-1 trading plan ensures transparency and reduces the risk of insider trading, which benefits all stakeholders.
Key Dates
| Date | Description |
|---|---|
| 03/01/2024 | Date of adoption of the Rule 10b5-1 trading plan. |
| 02/10/2025 | Date of the stock option exercise and share sale. |
| 02/12/2025 | Date of the Form 4 filing. |
| 05/24/2033 | Expiration date of the stock options. |
Keywords
Form 4, SpringWorks Therapeutics, SWTX, Director, Stock Options, Share Sale, Rule 10b5-1, Insider Trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.